Results 81 to 90 of about 6,607 (210)

Engineered Elastin‐Like Polypeptides: Intelligent Self‐Assembling Platforms for Biomedical Application

Small Structures, Volume 7, Issue 3, March 2026.
Armed with unique structural and functional properties, elastin‐like polypeptides attract their attentions as programmable materials in biomedical applications, including fusion tags for protein and nucleic acid purification; nanocarriers for protein, chemotherapeutics, and imaging agent delivery; hydrogels for tissue regeneration, 3D model ...
Yang Yuan, Chen Zeng, Zichun Chen, Zhuoga Ciren, Qinran Yu, Chuanbo Wang, Hui Mao, Gang Li, Weizhi Chen, Xiqun Jiang   +9 more
wiley   +1 more source

Immunotoxin mediated killing of clonable T-lymphocytes infiltrating an irreversibly rejected human renal allograft

, 1989
We isolated and treated in vitro with a novel CD5-specific saporin immunotoxin, referred to as OKT1-SAP, the cells infiltrating an irreversibly rejected renal allograft from a patient who rejected while on cyclosporine plus steroids and then failed to ...
S. Siena, M. Bregni, D. A. Lappi, G. Bonadonna, A. M. Gianni, A. Formosa, B. Brando   +6 more
core   +2 more sources

Advanced Human Immune Cell‐Organoid Co‐Cultures for Functional Testing of Cancer Nanovaccines

Advanced Science, Volume 13, Issue 10, 18 February 2026.
Pancreatic ductal adenocarcinoma remains difficult to treat. We establish an organoid–immune co‐culture using patient‐derived organoids and matched T‐cells to assess cancer vaccines. A mesothelin‐targeted nanovaccine activates antigen‐specific T‐cells, increases IFN‐γ, and targets MSLN+ organoids.
Nathalia Ferreira, David Agorku, Andre Rosa, Julia Roosz, Lena Christ, Nicole Anderle, Ajinkya Kulkarni, Abir Hussein, Sana S. Sayedipour, Omar F. Luna, Tobias Legler, Philipp Ströbel, Fernando Albericio, Luis Cruz, Phillipp Beckhove, Peter Loskill, Frauke Alves, M. Andrea Markus, Fernanda Ramos‐Gomes   +18 more
wiley   +1 more source

Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors

Toxins, 2018
LMB-100 is a mesothelin-targeted recombinant immunotoxin (iTox) that carries a modified Pseuodomonas exotoxin A (PE) payload. PE kills cells by inhibiting synthesis of new proteins.
Salma El-Behaedi, Rebekah Landsman, Michael Rudloff, Emily Kolyvas, Rakan Albalawy, Xianyu Zhang, Tapan Bera, Keith Collins, Serguei Kozlov, Christine Alewine   +9 more
doaj   +1 more source

Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components

Toxins, 2011
Immunotoxins and antibody-drug conjugates are protein-based drugs combining a target-specific binding domain with a cytotoxic domain. Such compounds are potentially therapeutic against diseases including cancer, and several clinical trials have shown ...
Luigi Cattel, Paola Brusa, Franco Dosio
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Site-Specific PEGylation of Recombinant Immunotoxin DAB389IL-2: Structural and Functional Assessment

Research in Molecular Medicine, 2019
Background: DAB389IL-2 is considered a fusion immunotoxin and it is used for the CTCL therapy. DAB389IL-2 includes of two distinct portions; the catalytic domain of diphtheria toxin and IL-2. DAB389IL-2 duo to the presence of a free cysteine residue (Cys
Nasrin Zarkar, Mohammad Ali Nasiri Khalili, Sirus Khodadadi, Mehdi Zeinoddini, Maryam Ghodrati Siahmazgi, Nasrin Faramarzi   +5 more
doaj  

Targeted Toxins in Brain Tumor Therapy

Toxins, 2010
Targeted toxins, also known as immunotoxins or cytotoxins, are recombinant molecules that specifically bind to cell surface receptors that are overexpressed in cancer and the toxin component kills the cell.
Walter A. Hall, Yan Michael Li
doaj   +1 more source

Reduction of graft-versus-host reactivity after small bowel transplantation: ex vivo treatment of intestinal allografts with an anti-T cell immunotoxin

, 1992
SUMMARY A specific T lymphocyte immunotoxin was used to pre-treat small bowel grafts in an attempt to prevent graft-versus-host (GVH) reactivity and GVH disease in a rat transplant model.
B A PRICE, J W FABRE, C L INGHAM CLARK, R F M WOOD, P W CRANE, G J SMITH, P A LEAR   +6 more
core   +1 more source

Targeted Diphtheria Toxin-Based Therapy: A Review Article

Frontiers in Microbiology, 2019
Cancer remains one of the leading causes of death worldwide. Conventional therapeutic strategies usually offer limited specificity, resulting in severe side effects and toxicity to normal tissues.
Fatemeh Shafiee, Marc G. Aucoin, Ali Jahanian-Najafabadi   +2 more
doaj   +1 more source